Clovis Oncology (CLVS) Defended at SunTrust
Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.
In addition to Piper (noted earlier), SunTrust is out defending Clovis Oncology (NASDAQ: CLVS) saying there nothing significantly new in the data. Shares of CLVS are down 13.7% after trading down nearly 30% earlier.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UPDATE: Chardan Capital Markets Starts Clovis Oncology (CLVS) at 'Sell' With Price Target of $15
- Akamai (AKAM) PT Raised to $65 at Stifel
- UPDATE: Dr Pepper Snapple Group (DPS) Said in Talks to Buy Bai Brands - Reuters
Create E-mail Alert Related CategoriesAnalyst Comments, Trader Talk
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!